Outcome | Inflammatory biomarker | Model | C index without inflammatory biomarker | C index with inflammatory biomarker | p Value |
---|---|---|---|---|---|
Stroke or systemic embolism | IL-6 | CHA2DS2-VASc | 0.67 | 0.67 | 0.1489 |
CHA2DS2-VASc+biomarkers | 0.70 | 0.70 | 0.6873 | ||
CRP | CHA2DS2-VASc | 0.67 | 0.67 | 0.1917 | |
CHA2DS2-VASc+biomarkers | 0.70 | 0.70 | 0.6670 | ||
All-cause mortality | IL-6 | CHA2DS2-VASc | 0.63 | 0.69 | <0.0001 |
CHA2DS2-VASc+biomarkers | 0.75 | 0.76 | <0.0001 | ||
CRP | CHA2DS2-VASc | 0.63 | 0.66 | <0.0001 | |
CHA2DS2-VASc+biomarkers | 0.75 | 0.75 | <0.0001 | ||
Cardiovascular mortality | IL-6 | CHA2DS2-VASc | 0.64 | 0.68 | <0.0001 |
CHA2DS2-VASc+biomarkers | 0.77 | 0.78 | 0.0013 | ||
CRP | CHA2DS2-VASc | 0.64 | 0.65 | <0.0001 | |
CHA2DS2-VASc+biomarkers | 0.77 | 0.77 | 0.2708 | ||
Major bleed | IL-6 | HAS-BLED | 0.63 | 0.65 | <0.0001 |
HAS-BLED+biomarkers | 0.68 | 0.68 | 0.0689 | ||
CRP | HAS-BLED | 0.63 | 0.63 | 0.1439 | |
HAS-BLED+biomarkers | 0.68 | 0.68 | 0.2819 |
The first model contains the CHA2DS2-VASc risk score or the HAS-BLED risk score for major bleeding outcomes, in addition to randomised treatment, region, use of warfarin within 7 days before randomisation, use of statin medication within 30 days before randomisation. The second model contains, in addition to the variables in the first model, the cardiovascular and renal biomarkers (NT-proBNP, Troponin I, GDF-15 and cystatin C).
CRP, C reactive protein.